Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx BioINK PD-L1 CTC Core Kit

IncellDx has launched its BioINK PD-L1 CTC Core Kit, a complete, pre-optimized tool to identify, enumerate, and quantify PD-L1 expression in circulating tumor cells. According to the firm, the kit includes the addition of a separate quantitative control cell cocktail — called OncoTect iO Control Cells — that combines PD-L1 positive epithelial cells, PD-L1 negative epithelial cells, and peripheral blood mononuclear cells. The tool allows labs to assess linearity and lower limits of detection for CTC enumeration with known quantities of cells in a lyophilized standard.

The firm's BioINK technology enables highly sensitive and specific quantification of protein or mRNA expression at a single-cell-by-cell resolution optimized for microfluidic chips. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.